Published in Neuro Oncol on September 23, 2016
Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med (2017) 1.40
Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. Oncoimmunology (2017) 0.75
Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther (2017) 0.75
Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment. Neuro Oncol (2017) 0.75
The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 7.71
SLAM (CDw150) is a cellular receptor for measles virus. Nature (2000) 6.07
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature (2011) 2.94
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol (1999) 2.34
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res (2003) 2.12
The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX (2009) 1.97
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res (2013) 1.86
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett (2003) 1.74
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol (2011) 1.63
Origin and differentiation of microglia. Front Cell Neurosci (2013) 1.58
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol (2010) 1.53
The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clin Cancer Res (2015) 1.52
Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol (2010) 1.42
Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res (2009) 1.42
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther (2014) 1.40
Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res (2006) 1.40
Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem (2005) 1.34
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res (2008) 1.33
Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther (2007) 1.32
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther (2008) 1.24
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther (2013) 1.22
A comparative review of cell culture systems for the study of microglial biology in Alzheimer's disease. J Neuroinflammation (2012) 1.21
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res (2014) 1.20
Measles virus causes immunogenic cell death in human melanoma. Gene Ther (2011) 1.19
Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res (2012) 1.17
PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol (2015) 1.16
Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin Dev Immunol (2013) 1.16
Emerging therapies for glioblastoma. JAMA Neurol (2014) 1.14
CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther (2006) 1.07
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther (2015) 1.06
Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther (2010) 1.03
Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor(s). J Virol (2002) 0.98
Cytotoxic cells in immunodeficient athymic mice. Immunopharmacol Immunotoxicol (1994) 0.96
Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol (2015) 0.95
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol (2009) 0.95
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
CD46 expression does not overcome the intracellular block of measles virus replication in transgenic rats. J Virol (1997) 0.92
EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy. Biomaterials (2013) 0.89
Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther (2012) 0.89
Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther (2012) 0.88
In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies. FASEB J (2003) 0.87
Medical management of high-grade astrocytoma: current and emerging therapies. Semin Oncol (2014) 0.80
MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol (2016) 0.75